Affimed (AFMD) Corporate Presentation summary

Company overview and leadership

• Focuses on developing innate cell engager (ICE®) therapies for solid and hematologic tumors, with over 500 patients treated across programs.

• Demonstrated clinical efficacy as monotherapy and in combination with NK cell therapy and checkpoint inhibitors.

• Leadership team and boards have extensive experience in life sciences and oncology.

Clinical pipeline and programs

• Three ongoing clinical programs: AFM24 (EGFR), Acimtamig/AFM13 (CD30), and AFM28 (CD123), targeting NSCLC, HL, PTCL, and AML.

• All programs have shown clinical efficacy, validating the approach of leveraging the innate immune system.

• Clinical updates for all assets are expected in 2025, with financial runway into Q4 2025.

AFM24 in NSCLC (EGFRwt and EGFRmut)

• AFM24 combined with atezolizumab in advanced/metastatic NSCLC showed 76% DCR and 21% ORR in EGFRwt, and 71% DCR and 24% ORR in EGFRmut cohorts.

• Manageable safety profile with most adverse events being mild or transient.

• Durable responses observed, with median PFS of 5.6–7.4 months, especially in patients without prior taxane exposure.

• Higher AFM24 exposure correlates with increased efficacy; dose escalation to 720 mg weekly planned to improve outcomes.